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EDITORIAL
Plasma RANTES: a molecular fingerprint of the
unstable carotid plaque?
Stephan Winnik1, Roland Klingenberg1, and Christian M. Matter1,2*
1Cardiovascular Research, Institute of Physiology, Zurich University and Cardiovascular Center, University Hospital Zurich, Switzerland; and 2Zurich Center of Integrative Human
Physiology (ZIHP), University of Zurich, Switzerland
This editorial refers to ‘Relationship between circulating
levels of RANTES (regulated on activation, normal
T-cell expressed, and secreted) and carotid plaque
characteristics: the Atherosclerosis Risk in Communities
(ARIC) Carotid MRI Study’, by S.S. Virani et al.
doi:10.1093/eurheartj/ehq367
Rupture of atherosclerotic plaques in epicardial coronary or
carotid arteries may lead to myocardial infarction or stroke—the
leading causes of morbidity and mortality in Western countries.1
Thus, timely detection of these unstable plaques before they
rupture is a great medical need.2 Non-invasive plaque visualization
using duplex ultrasound, computed tomography (CT) or magnetic
resonance imaging (MRI) provide the advantage of longitudinal ana-
lyses, but limitations exist in terms of moderate spatial resolution
and exposure to X-rays when using CT. Hence, their sensitivity
and specificity for detecting unstable atherosclerotic plaques is
moderate. To optimize the cost–benefit ratio, we need to tailor
our tools for identifying patients with increased cardiovascular
risk harbouring plaques prone to rupture.
Ideally, high-resolution plaque imaging is combined with one or
several emerging biomarkers that provide incremental information
about plaque biology and patient prognosis. Adding to the wealth
of experimental, clinical, and epidemiological evidence that ident-
ified inflammation as an integral element throughout the different
stages of atherosclerosis, biomarkers of inflammation have been
validated in clinical trials.1,3 Among them, C-reactive protein
stands out as the prototype inflammatory biomarker that adds
valuable information in terms of cardiovascular risk stratification.1
However, in the absence of firm evidence for a causal role of
C-reactive protein in atherosclerosis by applying Mendelian ran-
domization for gene variants in the C-reactive protein locus,4
C-reactive protein does not meet the criteria of a cardiovascular
risk factor. Several additional inflammatory mediators involved in
experimental atherogenesis have been tested clinically with
regard to their prognostic value. However, short half-life, low
plasma levels, and susceptibility to both in vivo and ex vivo con-
founding factors such as altered plasma levels by heparin or
release from platelets during coagulation complicate the quest
for THE biomarker of cardiovascular risk. Moreover, given the
complex interplay of a multitude of inflammatory mediators in
atherogenesis, it appears likely that a set of multiple biomarkers
will be needed for complete risk assessment.
The ideal cardiovascular inflammatory biomarker is a stable
protein, sufficiently present in a non-invasively accessible compart-
ment for cost-effective and reproducible detection. Reflection of
the stage and progression of atherosclerosis would confer both
prognostic value and its implementation as a monitoring tool for
emerging anti-inflammatory therapies.3 C-reactive protein does
not combine all of these desirable criteria but, to date, portrays
the closest approximation. Therefore, the characteristics described
for C-reactive protein are what emerging biomarkers such as
RANTES need to run up against.
The CC chemokine ligand-5 (CCL5/RANTES, regulated upon
activation, normal T cell expressed, and secreted) is an inflamma-
tory cytokine that recruits leucocytes into sites of inflammation.
Rapid release from activated platelets leads to deposition of
RANTES on activated endothelia, and induces monocyte and T
cell arrest, followed by transendothelial diapedesis (Figure 1).5
CXCL4, another platelet-derived chemokine, has been reported
to augment the RANTES-mediated chemotaxis and vice versa,
potentially through the formation of CXCL4–CCL5 heterodimers.6
RANTES is also highly expressed within the atheroma, where it
colocalizes with T cells, monocyte-derived macrophages, and
smooth muscle cells (Figure 1).7 Animal studies have highlighted
the pro-atherogenic effects of both RANTES and its receptor
CCR5: targeted disruption of the RANTES receptor CCR5,
present on both plaque-resident and circulating leucocytes as
well as on endothelial cells, reduced advanced atherosclerotic
lesions in mice.6 In parallel, pharmacological blockade using the
antagonizing antibody MET-RANTES diminished atherosclerosis
and decreased both mononuclear cell infiltration and the T
helper 1 (Th1)-type immune response in atherosclerotic mice.6
However, in patients with coronary artery disease (CAD), the
value of plasma RANTES levels remains controversial. In patients
with stable CAD RANTES levels were decreased compared with
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healthy controls. 8 In contrast, transiently raised levels of RANTES
were observed in ischaemic patients with unstable angina com-
pared with patients with stable CAD.9 Therefore, the value of
the RANTES plasma level as a biomarker or prognostic factor in
CAD warrants further investigation.
In this issue of the EHJ Virani and colleagues10 report the inves-
tigation of the association between plasma levels of RANTES and
morphological plaque parameters using MRI in a large cohort of
the Atherosclerosis Risk in Communities (ARIC) study. High-risk
patients with increased carotid intima-media thickness were
selected by carotid duplex ultrasound and underwent carotid
MRI. The authors found that plasma RANTES levels positively cor-
related with total plaque burden.
Using C-reactive protein as a reference inflammatory biomarker,
the authors describe a weak correlation between C-reactive
protein and RANTES plasma levels. This association, however,
Figure 1 Plasma RANTES (regulated upon activation, normal T cell expressed and secreted/CCL5) and atherosclerosis: secretion of
RANTES by activated platelets and expression of its receptor CCR5 on circulating monocytes, T cells and activated endothelial cells
enhance leucocyte arrest and transendothelial diapedesis, thereby promoting plaque development. Virani and colleagues investigated plaque
morphology using magnetic resonance imaing and plaque biology assessing RANTES plasma levels in a large cohort. Their key findings
(blue) indicate the potential of plasma RANTES levels to identify the extent of atherosclerosis as assessed by magnetic resonance imaing. Evalu-
ation of this emerging inflammatory biomarker for risk stratification or potential therapeutic intervention needs to be assessed in future studies.
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was not reported in patients receiving statins. These findings are
intriguing and necessitate future research to prospectively assess
the effects of statins on both circulating C-reactive protein and
RANTES. Ethnic variations of RANTES levels as described by
Virani and coworkers deserve distinct attention since specificity
and sensitivity may vary markedly. In addition, low plasma
RANTES levels ranging magnitudes below the respective C-
reactive protein levels as well as its limited stability may impede
routine detection of RANTES as a biomarker in CAD. Moreover,
originating to a considerable extent from platelets, ex vivo release
during coagulation of plasma samples may confound results. On
the other hand, the skewed distribution of plasma RANTES and
its putative causative role in experimental atherosclerosis might
redeem some of the impairments to its use as a biomarker.
Since plasma RANTES levels may not reflect its expression
pattern in atherosclerotic lesions, a correlation with the biological
activity of RANTES in atherogenesis remains to be determined.
Therefore, prospective clinical studies correlating circulating
RANTES and C-reactive protein levels with plaque histology and
clinical presentation appear critical for the evaluation of the bio-
logical significance of plasma RANTES levels.
To evaluate RANTES as a therapeutic target in atherosclerosis,
the risk–benefit ratio of RANTES antagonism deserves attention.
Importantly, the atheroprotective effects of MET-RANTES11 in
rodents appear to be outweighed by an impaired systemic
immune response.12 Therefore, CCL5–CXCL4 heterodimers
may emerge as a better therapeutic alternative mediating
reduced monocyte recruitment into the atherosclerotic plaque
and attenuating its growth.13
To date, clinical evidence for a role of RANTES in atherosclero-
sis is scarce. A word of caution along this line comes from current
large-scale genome-wide association studies. In this regard, genetic
evidence substantiating a critical role for RANTES in CAD is
lacking, whereas in type 1 diabetes RANTES single nucleotide poly-
morphisms were found to be associated with RANTES serum con-
centrations and the development of disease.14
Virani and colleagues provide data correlating circulating
RANTES with plaque burden and lipid-core volume (in univariate
analysis). However, a clear association with further features of
unstable plaques was not detected. Unexpectedly, elevated
RANTES plasma levels were associated with a thicker fibrous
cap, suggestive of a more stable plaque phenotype. The limited
spatial and temporal resolution of MRI in pulsating carotid arteries
may, at least in part, explain this shortcoming. Moreover, preselect-
ing patients using duplex ultrasound might have introduced a bias.
Plasma RANTES—a molecular fingerprint of the unstable
carotid plaque? Circulating RANTES levels may help to identify
the extent of atherosclerosis but appear to be of limited value
for the identification of unstable lesions. As an inflammatory bio-
marker, plasma RANTES lags behind C-reactive protein regarding
its biochemical properties and stable correlation with inflam-
mation. Reflecting an intricate pathophysiological process in ather-
osclerosis, however, RANTES may take hold as a biomarker of the
plaque burden in atherosclerosis. Since statins appear to blunt the
observed correlation, broad clinical applicability in patients on this
lipid-lowering medication appears questionable. Moreover, assess-
ment of the prognostic value of circulating RANTES or its signifi-
cance as a therapeutic target warrants future research.
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